Antifibrinolytic Therapy and Perioperative Considerations.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29200009.
- Also identified by DOI 10.1097/ALN.0000000000001997 and PMC identifier 5811331.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fibrinolysis is a physiologic component of hemostasis that functions to limit clot formation. However, after trauma or surgery, excessive fibrinolysis may contribute to coagulopathy, bleeding, and inflammatory responses. Antifibrinolytic agents are increasingly used to reduce bleeding, allogeneic blood administration, and adverse clinical outcomes. Tranexamic acid is the agent most extensively studied and used in most countries. This review will explore the role of fibrinolysis as a pathologic mechanism, review the different pharmacologic agents used to inhibit fibrinolysis, and focus on the role of tranexamic acid as a therapeutic agent to reduce bleeding in patients after surgery and trauma.
Medical subject headings
- Antifibrinolytic Agents
- Blood Loss, Surgical
- Fibrinolysis
- Perioperative Care
- Tranexamic Acid